These results reveal evidence for the role of SOX2-OT in HNSCC progression and metastasis by binding to ILF3, which may serve as a therapeutic target and prognostic biomarker in HNSCC. The gene discussed is OXT; the disease is head and neck squamous cell carcinoma.